Domestic pharmaceutical firms mired in lackluster performance

Published: 2004-04-26 07:00:00

Updated: 2004-04-26 07:00:00

Influenced by sluggish OTC sales amid domestic business slump after implementation of SDP function in 2000, Korean pharmaceutical firms are feeling the pinch from lower growth in sales and net incomes, while foreign-invested pharmaceutical firms have enjoyed double-digit growth rates in their ann...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK